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 Pregnancy is characterized by specific changes in thyroid physiology. First, the requirements for dietary iodine 
increase substantially, which is due to the increased thyroid hormone formation, the enhanced iodine metabolism, 
the increased loss of this nutrient, etc. According to the current recommendations, the supply of iodine during 
gestation, and also during lactation, should be at least 250 micrograms daily. Therefore, additional iodine 
supplementation is advised at the level of at least 150 micrograms daily to be administered to every pregnant and 
lactating woman. According to current recommendations, this additional iodine supplementation is also 
recommended in women who are going to be pregnant. Thyroid hyperstimulation, caused by human chorionic 
gonadotrophin (hCG) at the end of the first trimester, is another physiological change during pregnancy. 
Concerning thyroid disorders in pregnant women, thyroid dysfunctions, i.e. hypo- and hyperthyroidism, are most 
frequent. The diagnosis is based on abnormal values of thyroid hormones and thyrotropin concentrations, although 
reference ranges differ substantially from those accepted for general population. Thus, the interpretation of 
obtained results are difficult. According to the current recommendations, the estimated upper limit of TSH 
concentration during preconception and pregnancy is 2.5 mIU/L, however still some difficulties in the 
interpretation of results occur mainly in the first trimester. In turn, the lack of reference ranges for thyroid 




 trimesters. Thyroid antibodies 
should be screened before and/or during pregnancy and possibly monitored in subjects with thyroid dysfunction, 
especially with hyperthyrodism. Both thyroid dysfunctions are predominantly of autoimmune etiology, with 
hypothyroidism occurring much more frequently. The prevalence of hypothyroidism, especially of its subclinical 
form during preconception and gestational state, is estimated at the level of 10-15% or possibly higher. 
The etiology of hypothyroidism is usually associated, as in the general population, with Hashimoto’s thyroiditis. 
Replacement therapy with levothyroxine (L-thyroxine) is the treatment of choice in hypothyroidism. Hypothyroid 
patients on L-thyroxine replacement should be carefully monitored to keep TSH and thyroid hormone 
concentrations in recommended ranges before conception and during pregnancy. Patients with pre-existing 
hypothyroidism generally require increased L-thyroxine doses during pregnancy. In turn, hyperthyroidism in 
pregnancy is usually associated with Graves’ disease. Medical treatment in hyperthyroid pregnant women is the 
management of choice, with propylthiouracil being the preferred antithyroid drug in the first trimester and 




 trimesters. Careful control of maternal thyroid function is 
required during antithyroid drug treatment to avoid fetal hypothyroidism. The increased concentration of hCG in 
the first trimester assumes relatively frequently the form of gestational transient thyrotoxicosis. This form of 
thyrotoxicosis constitutes the separate entity; it usually needs no treatment, although in some patients with severe 
clinical symptoms the treatment with antithyroid drugs may be useful. Summing up, the diagnostic and treatment 
procedures in pregnant women with thyroid dysfunction are characterized by certain specificity and should be 
updated due to results of ongoing epidemiological studies, especially those on establishment of reference ranges of 
thyroid hormones. 
